ReviewMemorias do Instituto Oswaldo Cruz2024
Drug screening and development cascade for Chagas disease: an update of in vitro and in vivo experimental models.
Review in Memorias do Instituto Oswaldo Cruz, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Pyridyl-Thiazole-Thiosemicarbazones as Antitrypanosomatidae Agents: Design, Synthesis, and In Silico Profiling.ChemMedChem · 2026Article
- Phenotypic Analysis of the Anti-Molecules (Basel, Switzerland) · 2026Article
- Multitarget Therapeutic Strategies for Chagas Disease: Natural Compounds, Antimicrobial Peptides, and Cell-Based Immunomodulation.Infectious disease reports · 2026Review
- In Vivo Trypanocidal Activity of the Drug Disulfiram Combined with Benznidazole.ACS infectious diseases · 2026Article
- A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 1: setting the stage.The Journal of antimicrobial chemotherapy · 2026Review
- The activity, selectivity and pharmacological profile of imatinib derivates againstParasitology · 2026Article
- A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 2: from molecule to confirmed hit.The Journal of antimicrobial chemotherapy · 2026Review
- Haemanthidine-Containing Alkaloid Fraction fromACS omega · 2026Article
- Effect ofBiology · 2026Article
- Advances and challenges in the search for new treatments for Chagas disease.Memorias do Instituto Oswaldo Cruz · 2026Review
- Cafestol and kahweol: coffee diterpenes with trypanocidal activity and cardioprotective effects.Frontiers in cellular and infection microbiology · 2026Article
- Evaluation of the trypanocidal and immunomodulatory effects of LDT409, a cardanol derivative from cashew nut shell liquid.Frontiers in immunology · 2026Article
- Pyrazole-Imidazoline Derivative Prevents Cardiac Damage and Mortality in AcutePharmaceuticals (Basel, Switzerland) · 2025Article
- Anti-Molecules (Basel, Switzerland) · 2025Article
- Amiodarone and Ravuconazole Combination Potentiates Chemotherapy against Drug-Resistant Trypanosoma cruzi Strains.ACS omega · 2025Article
- The impact of probiotic administration on experimental in vitro and in vivo infection by Trypanosoma cruzi.Memorias do Instituto Oswaldo Cruz · 2025Article
- In vitro and in vivo studies on the activity and selectivity of butoconazole in experimental infection by Trypanosoma cruzi.Memorias do Instituto Oswaldo Cruz · 2025Article
- Efficacy of sulfonamides targeting malic enzyme in an animal model of Chagas disease.Frontiers in pharmacology · 2025Article
- Instrument-Free Point-of-Care Diagnostic for Leishmania Parasites.Diagnostics (Basel, Switzerland) · 2024Article
Corrections and comments
- Erratum issuedERRATUM.2024
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chagas disease is a tropical neglected disease that affects millions of people worldwide, still demanding a more effective and safer therapy, especially in its chronic phase which lacks a treatment that promotes substantial parasitological cure. The technical note of Romanha and collaborators published in 2010 aimed establish a guideline with the set of minimum criteria and decision gates for the development of new agents against Trypanosoma cruzi with the focus on developing new antichagasic drugs. In this sense, the present review aims to update this technical note, bringing the state of the art and new advances on this topic in recent years.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.